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Abstract
Background: Silibinin has been known for its role in anti-cancer and radio-protective effect. Radiation therapy for
treating lung cancer might lead to late-phase pulmonary inflammation and fibrosis. Thus, this study aimed to
investigate the effects of silibinin in radiation-induced lung injury with a mouse model.
Methods: In this study, we examined the ability of silibinin to mitigate lung injury in, and improve survival of,
C57BL/6 mice given 13 Gy thoracic irradiation and silibinin treatments orally at 100 mg/kg/day for seven days
after irradiation. In addition, Lewis lung cancer (LLC) cells were injected intravenously in C57BL/6 mice to
generate lung tumor nodules. Lung tumor-bearing mice were treated with lung radiation therapy at 13 Gy and
with silibinin at a dose of 100 mg/day for seven days after irradiation.
Results: Silibinin was shown to increase mouse survival, to ameliorate radiation-induced hemorrhage, inflammation
and fibrosis in lung tissue, to reduce the number of inflammatory cells in the bronchoalveolar lavage fluid (BALF) and
to reduce inflammatory cell infiltration in the respiratory tract. In LLC tumor injected mice, lung tissue from mice
treated with both radiation and silibinin showed no differences compared to lung tissue from mice treated with
radiation alone.
Conclusions: Silibinin treatment mitigated the radiation-induced lung injury possibly by reducing inflammation and
fibrosis, which might be related with the improved survival rate. Silibinin might be a useful agent for lung cancer
patients as a non-toxic complementary approach to alleviate the side effects by thorax irradiation.
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Background
Radiotherapy has been used to treat lung cancer, but be-
cause radiation can damage normal tissues, many com-
plications may develop in patients receiving lung
irradiation [1]. Radiation-induced pulmonary damage to
normal lung tissue can lead to early phase pneumonitis
and late phase fibrosis months to years after irradiation,
which can affect a patient’s quality of life [2]. An animal
model for pulmonary fibrosis has been established using
total body irradiation at 15 Gy [3]. Previous studies had
shown that fibrosis was not induced in C3H/HeJ and
CBA/J mice but was found in C57BL/6 mice during the
late phase after thorax irradiation [4,5]. Although radio-
protective agents, including soy isoflavone, have been
found to mitigate the inflammation and fibrosis induced
by irradiation, the mechanism of pulmonary fibrosis in-
duced by thorax irradiation is still unknown; however,
inflammation was proposed to involve the radiation-
induced fibrosis formation [6].
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Silibinin, a standardized extract from the fruits and
seeds of milk thistle, is the major active constituent of
silymarin and is used clinically and consumed as a diet-
ary supplement for liver disease [7,8]. Silibinin has
shown promising and potential anti-tumor efficacy in
several cancers including lung cancer models [9-11].
Previous research showed that the oral administration of
silibinin produced a profound effect in protecting mice
against radiation-induced mortality and preventing DNA
damage in vitro [12]. However, the potential protective
effect of silibinin against radiation-induced lung fibrosis
is unknown.
In this study, we administrated silibinin to irradiated
C57BL/6 mice to examine the potential radioprotective
effect of silibinin in the normal lung tissue. Changes in
the number of inflammatory cells were evaluated in
bronchoalveolar lavage fluid (BALF), and the histologic
change of lung tissue was investigated to verify the in-




Six-week-old female C57BL/6 mice (Central Lab. Animal
Inc., Seoul, Korea) were used after one week of quaran-
tine and acclimatization. The animals were maintained
in a room at 23 ± 2°C, with a relative humidity of 50 ±
5%, artificial lighting from 08:00–20:00 and 13 ~ 18 air
changes per hour. The mice were given a standard la-
boratory diet and water ad libitum. All experimental
procedures were carried out in accordance with the NIH
Guidelines for the Care and Use of Laboratory Animals
and were conducted following a protocol approved by
the Institutional Animal Care and Use Committee of the
Dongnam Institute of Radiological and Medical Sciences.
The animals were cared for in accordance with the dic-
tates of the National Animal Welfare Law of Korea.
Radiation and silibinin treatment
Each mouse was anesthetized with tiletamine/zolazepam
(Zoletil 50®; Virak Korea; Seoul, Korea) and restrained
on a tray. Mice were exposed to whole thorax radiation
(13 Gy; dose rate 3.8 Gy/min) using 6 MV high-energy
photon rays (ELEKTA, Stockholm, Sweden) with a
1.5 cm bolus on the surface. The radiation dose was pre-
scribed at the midline of body thickness. Dose variation
inside the lung was estimated to be within 50 ± 5% of
the prescribed dose. Sham-irradiated mice were treated
in the same manner but without radiation. A dose of
100 mg/kg silibinin was dissolved in PBS and was
treated P.O. for 7 consecutive days after irradiation. The
dose and dosage was considered optimal for radioprotec-
tion and blood concentration as reported earlier [12,13].
Control mice received the same dose and dosage of
vehicle in the same manner. Mice were sacrificed at 80
or 200 days after irradiation.
Survival measurement
Survival was monitored daily and was reported as the
percentage of animals surviving until 200 days after ir-
radiation. Each treatment group consisted of 10 mice.
Animals were sacrificed when in a moribund state.
Bronchoalveolar lavage fluid analysis
At 80 and 200 days after thorax irradiation, mice were
anesthetized by intraperitoneal injection of Zoletil, and a
tracheostomy was performed. Bronchoalveolar lavage fluid
(BALF) was obtained by a recently described method [14].
The total number of inflammatory cells was determined
by counting the cells in at least five squares of a
hemocytometer after cell viability testing with Trypan blue
staining. To determine the differential cell counts, 100 μL
of BALF was centrifuged (200 g, 4°C, 10 min) onto slides
using a Cytospin (Hanil Science Industrial Co.; Seoul,
Korea). The slides were dried, and the cells were fixed and
stained with the Diff-Quik® staining reagent (B4132-1A;
IMEB Inc.; Deerfield, IL, USA) according to the manu-
facturer’s instructions. The numbers of macrophages,
neutrophils, and lymphocytes were calculated using the
percentages obtained multiplied by the total yield. Im-
ages of slides were obtained using a digital camera
mounted on a microscope (Nikon Eclipse 80i; Nikon
Corporation; Tokyo, Japan). Differential count of in-
flammatory cells in BALF was performed in a double-
blind screen by two independent pathologists. The
average cellular area of individual macrophages was cal-
culated using Image-Pro Plus image analyzing software
(Media Cybernetics; Bethesda, MD, USA). The percent-
age of multinucleated cells was calculated by dividing
the total cell count (approximately 400 cells) by the
scored cells [15].
Histopathology
After BALF samples were obtained, lung tissue was fixed
in 10% buffered formalin and embedded in paraplast
wax to prepare 4 μm thick tissue sections of lung tissue
for hematoxylin-eosin staining. Two tissue sections from
four different parts of the lung from each animal were
prepared for histological examination. Images of lung
sections were obtained using a digital camera mounted
on a microscope (Nikon Eclipse 80i; Nikon Corporation;
Tokyo, Japan). Quantification was performed using
Image-Pro Plus image analyzing software (Media Cyber-
netics; Bethesda, MD, USA).
Each tissue section was given a score from 0–4 based
on the amount of area affected by interstitial inflamma-
tion, alveolar wall thickening, peribronchial inflammation
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and interstitial edema (0 ≤ 10%, 1 = up to 30%, 2 = up to
50%, 3 = up to 70%, 4 ≥ 70%) [16].
Lung fibrosis was evaluated in lung sections stained
with Masson’s trichome (n ≥ 4) by examining the amount
of collagen fibers [14]. Each lung section was given a
score from 0–3 depending on collagen fiber thickness
and dispersion. Lung sections were analyzed and photo-
graphed (Nikon Eclipse 80i; Nikon Corporation; Tokyo,
Japan). The degrees of inflammation and fibrosis in the
lung tissue were scored in a double-blind screen by two
independent pathologists. In case of fibrosis, we add-
itionally performed quantitative analysis using Image-
Pro Plus image analyzing software (Media Cybernetics;
Bethesda, MD, USA) [17].
Establishment of lung tumor model
The C57BL/6 mouse Lewis lung cancer (LLC) cells (Ko-
rean Cell Line Bank; Seoul, Korea) were cultured in
RPMI culture medium containing 7% heat-inactivated
fetal bovine serum with supplements. LLC cells, at 1 ×
106 cells in 200 ml DPBS, were injected intravenously
into the tail vein of seven-week-old female C57BL/6
mice. The mice were randomly divided into the follow-
ing four groups: vehicle + sham irradiation group (n =
10), silibinin + sham irradiation group, vehicle + 13 Gy
irradiation group, and silibinin + 13 Gy irradiation group.
Figure 1A shows the timeline for establishment of the
lung tumor model. Multiple metastatic lung cancer was
established within one week post injection as judged by
parallel animals that were sacrificed and evaluated histo-
logically. At this time, the mice received whole thorax ir-
radiation (13 Gy), and 100 mg/kg/day silibinin was
administered orally for 7 days after irradiation. Lung
weights and lung cancer nodule measurements were de-
termined using a micro-CT scanner (NFR Polaris-G90;
NanoFocusRay; Jeonju, Korea).
Statistical analysis
The data are reported as the mean ± SEM. The data were
analyzed using one-way analysis of variance (ANOVA)
followed by the Student-Newman-Keuls post hoc test for
multiple comparisons. In all cases, a p value < 0.05 was
considered significant.
Results
Effects of silibinin treatment on the survival rate of
irradiated mice
To determine the effect of silibinin treatment after a sin-
gle dose of radiation, C57BL/6 J mice were exposed to
13 Gy whole-thorax irradiation, and some groups were
Figure 1 (A) Representative photographs and radiographs of mouse lung tissue. Lung weight (B) and number of tumor nodules (C) at 21 days
following irradiation. The data are reported as means ± SEM (n = 7 per group). *p < 0.05 vs. sham-irradiated controls.
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treated with silibinin after radiation. Although all mice
irradiated with 13 Gy survived to 170 days following ir-
radiation, the survival rate of this group dropped to 40%
at 200 days after thorax irradiation (Figure 2B). However,
all of the mice treated with silibinin after irradiation sur-
vived until 200 days, and this survival rate was increased
compared with the mice exposed to radiation alone
(Figure 2B).
Effects of silibinin on the level of inflammatory cells in
the BALF of irradiated mice
To evaluate the effect of silibinin on inflammatory cells
in the BALF, total cells including neutrophils, lympho-
cytes, and macrophages were measured after whole-
thorax irradiation (Figure 3A). The total number of
BALF cells increased significantly at 80 days after irradi-
ation, and the cell number at 200 days increased further.
When the cellular component of BALF was evaluated,
significant increases were found in each cellular type,
both at 80 and 200 days (Figure 3B-E). However, at
80 days after irradiation, the number of total cells, lym-
phocytes, and macrophages in the BALF of irradiated
mice given silibinin were significantly decreased com-
pared with irradiation-only group (Figure 3B-E). Further-
more, at 200 days following thorax irradiation, the
number of total cells, neutrophils, and macrophages in
the BALF of irradiated mice given silibinin were signifi-
cantly down-regulated compared with irradiation-only
group (Figure 3B-E). These data indicate that silibinin
ameliorates the inflammatory response in the BALF of
mice following whole-thorax irradiation.
Changes in macrophage morphology in the BALF of
irradiated mice with silibinin treatment
Because the main cellular component of BALF is macro-
phage, macrophage morphology and multinucleated
macrophages were evaluated in the BALF of mice after
irradiation with and without silibinin treatment. In mice
treated with thorax irradiation alone, the macrophage
size was increased at 80 days, and enlarged macrophages
became notably evident at 200 days after irradiation
(Figure 4A and B). After silibinin treatment, the size of
macrophages in the BALF was significantly reduced com-
pared to those in the radiation-only group (Figure 4B).
BALF cells from control mice only occasionally con-
tained dividing macrophages. However, mice receiving
thoracic irradiation had a high frequency of multinucle-
ated macrophages at 80 and 200 days after irradiation
(Figure 4C). A decreased number of multinucleated
macrophages was observed in mice treated with silibinin
at 80 and 200 days following thoracic irradiation, al-
though the difference at 200 days was not significant.
Anti-inflammatory effects of silibinin in irradiated normal
lung tissue
To examine the changes in lung tissue after thoracic ir-
radiation combined with silibinin treatment, the extent
of inflammation in mice lung was assessed histologically
at 80 and 200 days after radiation. In sham control mice,
the lung tissue showed normal lung alveoli at 80 days
and some areas of thick alveolar septae at 200 days fol-
lowing irradiation (Figure 5A and J). Silibinin treatment
alone caused no changes in the morphology of the lung
alveoli compared to control mice (data not shown). In
the lung tissue of mice that received irradiation alone,
infiltration of inflammatory cells was evident at 80 and
200 days after thoraxic irradiation, and extensive hemor-
rhages were observed (Figure 5B and H). Irradiated mice
treated with silibinin in the post-irradiation period showed
an ameliorated inflammatory response as well as de-
creased alveolar septum thickness (Figure 5C and I).
When lung tissue inflammation was scored, the increased
inflammation score caused by irradiation was significantly
down-regulated after silibinin treatment both at 80 and
200 days following irradiation (Figure 5M).
Antifibrotic effects of silibinin in irradiated lung tissue
To determine the effect of silibinin on radiation-induced
fibrosis, Masson’s trichome staining for collagen was used
in the mouse lung tissue sections. In lung tissue from
sham control mice, staining of collagen was only seen
around vessels or bronchioles (Figure 6A and G). Collagen
staining was not seen in irradiated lung tissue until 80 days
after irradiation (Figure 6B), and 200 days after irradiation,
extensive collagen was detected in the lung tissue of irra-
diated mice, indicating radiation-induced fibrosis in lung
tissue (Figure 6H). In mice treated with silibinin, a signifi-
cant decrease in pulmonary fibrosis was detected in lung
tissue at 200 days after irradiation compared with
irradiation-only group (Figure 6I and M).
Effect of silibinin and radiation on lung cancer
To evaluate the effect of silibinin on lung cancer, LLC
cells were injected into the mice through the tail vein.
Mice bearing established LLC tumors were irradiated
Figure 2 Survival rate of mice treated with radiation alone and
radiation plus silibinin. The data are reported as means ± SEM (n = 5
per group).
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seven days after tumor injection, and silibinin was ad-
ministered orally at a dose of 100 mg/day for seven days
after thoracic irradiation. In the control group with un-
treated tumors, large tumor nodules were observed in
lung tissue sections (Figure 1A). Silibinin treatment
alone caused no significant differences in the number of
tumor nodules, indicating that silibinin treatment alone
was not related to enhancement of tumor growth
(Figure 1C). In irradiated mice treated with silibinin,
however, the number of tumor nodules was significantly
reduced in the lungs (Figure 1C).
Discussion
In the current study, we used a murine model to investi-
gate the use of silibinin as a new biological strategy to
reduce the adverse effects of radiotherapy for lung
Figure 3 Changes in bronchoalveolar lavage fluid (BALF) of C57BL/6 mice after irradiation. (A) Representative pictures of Diff-quick staining of
cytospin preparation at 80 and 200 days after thoracic irradiation. Changes in the number of total cells (B), neutrophils (C), lymphocytes (D), and
macrophages (E) in BALF from C57BL/6 mice. The data are reported as means ± SEM (n = 5 per group). *p < 0.05 vs. sham-irradiated controls.
#p < 0.05 vs. irradiated groups.
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cancer. The results showed that silibinin has the ability
to decrease inflammation and fibrosis in the lung.
Development of alveolitis and fibrosis is a known com-
plication of thoracic radiotherapy for cancer patients.
Many studies have attempted to establish the murine
model of pulmonary fibrosis by irradiation [5], and have
showed that radiation-induced lung response differs by
genetic background. Whereas C3H strain mice with
thorax irradiation only developed an inflammatory re-
sponse in the lung tissue, C57BL/6 mice with thorax ir-
radiation developed alveolitis followed by fibrosis in the
late phase [4,18]. The radiation-induced pulmonary re-
sponse of mice and the time to development of fibrosis
in mice have been observed to be similar to human pa-
tients receiving radiotherapy [19,20]. Previous studies
have shown that C57BL/6 J mice resisted death from
pneumonitis after irradiation doses less than 20 Gy and
died mainly of fibrosis between five and eight months.
[15]. Although many agent have been investigated for
ameliorating radiation effects [21,22], most studies have
administered these agents prior to radiation exposure
for demonstrating their efficacy as radioprotectors. How-
ever, there is a need to investigate an agent that is effect-
ive for reducing radiation-induced lung injury, because
administration and radiation schedules might differ be-
tween individuals, and lung might be the target organ in
possible radiological terrorism scenario with a radiolodi-
cal dispersion device [23]. In the present study, the sur-
vival rate of mice treated with 13 Gy of thorax
irradiation was 50%, which was consistent with the sur-
vival rate found in previous studies [4,15,18]. However,
irradiated mice treated with silibinin survived until the
end of this study (200 days after irradiation), indicating
the potential radioprotective effect of silibinin in normal
lung tissue.
Investigation has shown that many natural compounds
are able to enhance radiation-induced cancer cell de-
struction and protect normal tissues from radiation-
induced pulmonary injury [6,24]. However, the effects of
silibinin on radiation-induced lung injury remain un-
clear. Although the molecular and cellular mechanisms
of lung injury induced by thorax irradiation are not fully
Figure 4 Effects of radiation and silibinin on bronchoalveolar lavage fluid (BALF). (A) Representative pictures of Diff-quick staining of cytospin
preparation in BALF after thoracic irradiation with and without silibinin treatment. Changes in macrophage size (A) and percentage of multinucle-
ated macrophages in BALF at 80 and 200 days after thoracic irradiation. The data are reported as means ± SEM (n = 5 per group). *p < 0.05 vs.
sham-irradiated controls. #p < 0.05 vs. irradiated groups.
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determined, radiation-induced pulmonary inflammation
has been suggested as a possible mechanism. Many re-
ports have investigated radiation-induced lung damage
using BALF, because BALF is thought to reflect the in-
flammatory response of the lung. [15,25,26]. The
inflammatory response of BALF cells has been investi-
gated in the asthmatic response and in the response to
radiation [14,15]. Previous studies have suggested that
inflammatory cells including neutrophils [27], lympho-
cytes [28], and alveolar macrophages [29] may be involved
Figure 5 Changes in the histology of lung tissue from mice treated with radiation and silibinin. (A-F) 80 days after irradiation; (G-L) 200 days
after irradiation; (A, D, G, J) Lung tissue from sham-irradiated control; (B, E, H, K) Lung tissue from 13 Gy-irradiated mice; (C, F, I, L) Lung tissue
from 13 Gy-irradiated mice with silibinin treatment. Hematoxylin and eosin staining. Scale bars in low magnification present 300 μm. Scale bars in
high magnification present 50 μm. (M) Inflammation score from lung tissue at 80 and 200 days following irradiation. The data are reported as
means ± SEM (n = 5 per group). *p < 0.05 vs. sham-irradiated controls. #p < 0.05 vs. irradiated groups.
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in pulmonary inflammation and fibrosis. In the present
study, thorax irradiation induced a marked increase of in-
flammatory cells in the BALF at 80 days after irradiation
and a more prominent increase at 200 days. In addition,
the BALF macrophage, which is main cellular component
of BALF, was shown to increase in size after irradiation;
similarly, the number of multinucleated macrophages also
increased after irradiation. However, silibinin treatment
Figure 6 Masson’s trichrome staining for fibrosis in lung tissue sections from C57BL/6 mice treated with radiation and silibinin. (A-F) 80 days after
irradiation; (G-L) 200 days after irradiation; (A, D, G, J) Lung tissue from sham-irradiated control; (B, E, H, K) Lung tissue from 13 Gy-irradiated mice;
(C, F, I, L) Lung tissue from 13 Gy-irradiated mice with silibinin treatment. Masson’s trichome staining. Scale bars in low magnification present 300 μm.
Scale bars in high magnification present 50 μm. (M) Percentage of fibrosis from lung tissue evaluated at 80 and 200 days following irradiation. The data
are reported as means ± SEM (n = 5 per group). *p < 0.05 vs. sham-irradiated controls. #p < 0.05 vs. irradiated groups.
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attenuated the increased number of inflammatory cells and
morphological changes in macrophages in BALF both at
80 and 200 days after thorax irradiation, indicating that ad-
ministration of silibinin suppresses the inflammatory re-
sponse in the late phase after irradiation.
Thorax irradiation not only affected the inflammatory
cells in the BALF, but also triggered the chronic inflam-
matory responses in the lung tissue. It was previously
reported that pro-inflammatory cytokines, including
tumor necrosis factor (TNF)-α, interleukin (IL)-1β, IL-6,
and intercellular adhesion molecule 1, was induced by
thorax irradiation and have an important role in devel-
opment radiation-induced lung injury, including pneu-
monitis and fibrosis [30-33]. The mRNA levels of pro-
inflammatory cytokines in the lung tissue returned to
basal levels at 2 weeks, but significantly elevated at
8 weeks after irradiation with 12 Gy, indicating the bi-
phasic expression [30]. It was also demonstrated that
late cytokine expressions, such as TNF-α and IL-1β,
were found at the time the mice begin to develop fibro-
sis in C57BL/6 mice, suggesting the involvement of in-
flammatory responses in the radiation-induced fibrosis
[15]. In a mouse model of allergic inflammation, pre-
treatment of silibinin significantly attenuated the airway
inflammation, via downregulation of nuclear factor-
kappa B pathway [34]. In addition, silibinin has been
shown to target multiple cytokine-induced signaling
pathways and to down regulate iNOS expression in lung
cancer [35,36]. Other studies have indicated that silibinin
is pro-apoptotic, reverses cancer chemotherapy resist-
ance and acts in combination with other agents to have
a chemosensitizing effect in lung carcinoma cells [37]. In
the present study, a marked injury in the lung tissue was
observed and included multifocal hemorrhage and in-
flammatory infiltration. In addition, the presence of fi-
brosis was evaluated by Masson’s trichome staining, and
a marked increase in fibrotic collagen tissue was shown
at 200 days following thoracic irradiation. Our data
showed that silibinin down-regulated the inflammation
and fibrosis induced by irradiation in the lung tissue,
which was correlated with the increased survival rate by
thorax irradiation. The present study may provide a
basis for further studies to determine the protective
mechanisms of silibinin in radiation-induced lung injury,
although currently we are unable to determine the
precise effects of silibinin on pulmonary function. Fur-
thermore, further studies on the role of silibinin in
radiation-induced lung injury are required to determine
the precise mechanisms underlying pneumonitis and fi-
brosis, using appropriate animal models..
A major concern of any radioprotection study is that
the protective agent might theoretically protect the
tumor as well, making it useless for further development.
The attraction to investigate the role of silibinin as a
radiosensitizer and radioprotector in lung cancer is based
on its safety for clinical use. Silibinin has gained increasing
attention because of its association with beneficial effects
in various cancer chemoprevention [9,10,38]. Despite
these studies showing the efficacy of silibinin against lung
cancer, its utility in combination with radiation remains
unknown. In our study, no significant difference was ob-
served between vehicle treatment and treatment with sili-
binin and irradiation, indicates that silibinin does not
protect tumor cells from radiation.
Conclusions
Although cancer patients might benefit from radiotherapy,
this treatment is not devoid of side effects. This study
showed that in combination with radiation, silibinin in-
creases the survival rate, possibly by reducing the inflam-
mation and fibrosis induced by thorax irradiation, but that
silibinin itself does not have a radiotherapeutic effect on
tumor growth in cancer-bearing mice. Although the pre-
cise mechanism of the radioprotective effect of silibinin
remains unclear, silibinin is a possible adjunct to radiation
therapy and therefore might be clinically useful for lung
cancer patients requiring radiotherapy.
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